Recent developments and strategies for the discovery of TACE inhibitors

References

• Wong E, Cohen T, Romi E, et al. Harnessing the natural inhibitory domain to control TNFα Converting Enzyme (TACE) activity in vivo. Sci Rep. 2016;6(1):35598.
   PubMedGoogle Scholar
• Kato T, Hagiyama M, Ito A. Renal ADAM10 and 17: their physiological and medical meanings. Front Cell Dev Biol. 2018;6:153.
   PubMed Web of Science ®Google Scholar
• Chemaly M, McGilligan V, Gibson M, et al. Role of tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and associated proteins in coronary artery disease and cardiac events. Arch Cardiovasc Dis. 2017;110:700–711.
   PubMed Web of Science ®Google Scholar
• Klein T, Bischoff R. Active metalloproteases of the A Disintegrin and Metalloprotease (ADAM) family: biological function and structure. J Proteome Res. 2011;10:17–33.
   PubMed Web of Science ®Google Scholar
• Bode W, Gomis-Rüth FX, Stöckler W. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the ‘metzincins’. FEBS Lett. 1993;331:134–140.
   PubMed Web of Science ®Google Scholar
• Moss ML, Minond D. Recent advances in ADAM17 research: a promising target for cancer and inflammation. Mediators Inflamm. 2017;2017:9673537.
   PubMed Web of Science ®Google Scholar
• Moss ML, Sklair-Tavron L, Nudelman R. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008;4:300–309.
   PubMedGoogle Scholar
• Zhou J, Zhang Y, Zhou X, et al. An expeditious one-pot synthesis of 1,6-dideoxy-N-alkylated nojirimycin derivatives and their inhibitory effects on the secretion of IFN-gamma and IL-4. Bioorg Med Chem. 2008;16:1605–1612.
   PubMed Web of Science ®Google Scholar
• Duan JJ, Chen L, Wasserman ZR, et al. Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships. J Med Chem. 2002;45:4954–4957.
   PubMed Web of Science ®Google Scholar
• Grootveld M, McDermott MF. BMS-561392. Bristol-Myers Squibb. Curr Opin Invest Drugs. 2003;4:598–602.
   PubMedGoogle Scholar
• Qian M, Bai SA, Brogdon B, et al. Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinylmethoxy]phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humans. Drug Metab Dispos. 2007;35:1916–1925.
   PubMed Web of Science ®Google Scholar
• Clary L. Novel benzenesulphonamide compounds, method for synthesizing same, and the use thereof in medicine as well as in cosmetics. WO2011/001088. 2011.
   Google Scholar
• Thabet MM, Huizinga TW. Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr Opin Invest Drugs. 2006;7: 1014–1019.
   PubMed Web of Science ®Google Scholar
• Moss ML, Jin SLC, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumor-necrosis factor -alpha. Nature. 1997;385:733–736.
   PubMed Web of Science ®Google Scholar
• Murumkar PR, Giridhar R, Yadav MR. 3D-quantitative structure-activity relationship studies on benzothiadiazepinehydroxamates as inhibitors of tumor necrosis factor-alpha converting enzyme. Chem Biol Drug Des. 2008;71:363–373.
   PubMed Web of Science ®Google Scholar
• Murumkar PR, Gupta SD, Zambre VP, et al. Development of predictive 3D-QSAR CoMFA and CoMSIA models for beta-aminohydroxamic acid-derived tumor necrosis factor-alpha converting enzyme inhibitors. Chem Biol Drug Des. 2009;73:97–107.
   PubMed Web of Science ®Google Scholar
• DasGupta S, Murumkar PR, Giridhar R, et al. Studies on novel 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones as potential TACE inhibitors: design, synthesis, molecular modeling, and preliminary biological evaluation. Bioorg Med Chem. 2009;17:3604–3617.
   PubMed Web of Science ®Google Scholar
• Murumkar PR, Zambre VP, Yadav MR. Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors. J Comput Aided Mol Des. 2010;24:143–156.
   PubMed Web of Science ®Google Scholar
• Sengupta P, Puri CS, Chokshi HA, et al. Synthesis, preliminary biological evaluation and molecular modeling of some new heterocyclic inhibitors of TACE. Eur J Med Chem. 2011;46:5549–5555.
   PubMed Web of Science ®Google Scholar
• Murumkar PR, Sharma MK, Shinde AC, et al. Three-dimensional quantitative structure–activity relationship CoMFA/CoMSIA on pyrrolidine-based tartrate diamides as TACE inhibitors. Med Chem Res. 2013;22:4192–4201.
   Web of Science ®Google Scholar
• Murumkar PR, Sharma MK, Giridhar R, et al. Virtual screening-based identification of lead molecules as selective TACE inhibitors. Med Chem Res. 2015;24:226–244.
   Web of Science ®Google Scholar
• DasGupta S, Murumkar PR, Giridhar R, et al. Current perspective of TACE inhibitors: a review. Bioorg Med Chem. 2009;17:444–459.
   PubMed Web of Science ®Google Scholar
• Murumkar PR, DasGupta S, Chandani SR, et al. Novel TACE inhibitors in drug discovery: a review of patented compounds. Expert Opin Ther Pat. 2010;20:31–57.
   PubMed Web of Science ®Google Scholar
• Yadav MR, Gupta SD, Murumkar PR, et al. Small molecule selective TACE inhibitors: potential therapeutic agents. Adv Med Biol. 2010;3:77–116.
   Google Scholar
• Yadav MR, Murumkar PR, Zambre VP. Advances in studies on collagenase inhibitors. Exp Suppl. 2012;103:83–135.
   PubMedGoogle Scholar
• Murumkar PR, Giridhar R, Yadav MR. Novel methods and strategies in the discovery of TACE inhibitors. Expert Opin Drug Discov. 2013;8:157–181.
   PubMed Web of Science ®Google Scholar
• Nuti E, Casalini F, Santamaria S, et al. Selective Arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models. J Med Chem. 2013;56:8089–8103.
   PubMed Web of Science ®Google Scholar
• Nuti E, Casalini F, Avramova SI. Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models. J Med Chem. 2010;53:2622–2635.
   PubMed Web of Science ®Google Scholar
• Rossello A, Nuti E, Maresca A. ADAMs and ADAMts selective synthetic inhibitors. In drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. In: CT S, Winum JY, editors. Wiley series in drug discovery and development. Hoboken, NJ: John Wiley and sons; 2009. p. 591–645.
   Google Scholar
• Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev. 2006;25:115–136.
   PubMed Web of Science ®Google Scholar
• Georgiadis D. Yiotakis A specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem. 2008;16:8781–8794.
   PubMed Web of Science ®Google Scholar
• Condon JS, Joseph-McCarthy D, Levin JI, et al. Identification of potent and selective TACE inhibitors via the S1 pocket. Bioorg Med Chem Lett. 2007;17:34–39.
   PubMed Web of Science ®Google Scholar
• Li NG, Shi ZH, Tang YP. Discovery of selective small molecular TACE inhibitors for the treatment of rheumatoid arthritis. Curr Med Chem. 2012;19:2924–2956.
   PubMed Web of Science ®Google Scholar
• Guo Q, Wang Y, Xu D, et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15.
   PubMed Web of Science ®Google Scholar
• Ouvry G, Berton Y, Bhurruth-Alcor Y. Identification of novel TACE inhibitors compatible with topical application. Bioorg Med Chem Lett. 2017;27:1848–1853.
   PubMed Web of Science ®Google Scholar
• Aubert J. Utilization of TACE inhibitors for the treatment of acne. WO2009/004247. 2010.
   Google Scholar
• Boiteau JG, Ouvry G, Arlabosse JM. Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis. Bioorg Med Chem. 2018;26:945–956.
   PubMed Web of Science ®Google Scholar
• Tu G, Xu W, Huang H. Progress in the development of matrix metalloproteinase inhibitors. Curr Med Chem. 2008;15:1388–1395.
   PubMed Web of Science ®Google Scholar
• Rosner KE, Guo Z, Orth P. the discovery of novel tartrate-based TNF-alpha converting enzyme (TACE). Bioorg Med Chem Lett. 2010;20:1189–1193.
   PubMed Web of Science ®Google Scholar
• Guardiani C, Procacci P. The conformational landscape of tartrate-based inhibitors of the TACE enzyme as revealed by Hamiltonian replica exchange simulation. Phys Chem Chem Phys. 2013;15:9186–9196.
   PubMed Web of Science ®Google Scholar
• Dai C, Li D. Popovici-Muller J.2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett. 2011;21:3172–3176.
   PubMed Web of Science ®Google Scholar
• Banchelli M, Guardiani C, Tenori E, et al. Chemical-physical analysis of a tartrate model compound for TACE inhibition. Phys Chem Chem Phys. 2013;15:18881–18893.
   PubMed Web of Science ®Google Scholar
• Li D, Popovici-Muller J, Belanger DB. Structure and activity relationships of tartrate-based TACE inhibitors. Bioorg Med Chem Lett. 2010;20:4812–4815.
   PubMed Web of Science ®Google Scholar
• Banchelli M, Guardiani C, Sandberg RB, et al. Media effects in modulating the conformational equilibrium of a model compound for tumor necrosis factor converting enzyme inhibition. J Mol Struct. 2015;1091:65–73.
   Web of Science ®Google Scholar
• Ren S, Hesk D, McNamara P. Synthesis of [3H], [13C3, 15N], and [14C]SCH900567: an inhibitor of TNF-α (tumor necrosis factor alpha) converting enzyme (TACE). J Labelled Comp Radiopharm. 2014;57:632–636.
   PubMed Web of Science ®Google Scholar
• Yu W, Guo Z, Orth P, et al. Discovery and SAR of hydantoin TACE inhibitors. Bioorg Med Chem Lett. 2010;20:1877–1880.
   PubMed Web of Science ®Google Scholar
• Yu W, Tong L, Kim SH. Biaryl substituted hydantoin compounds as TACE inhibitors. Bioorg Med Chem Lett. 2010;20:5286–5289.
   PubMed Web of Science ®Google Scholar
• Shankar B. Compounds for the treatment of inflammatory disorders. WO/2010/0366638 . 2010.
   Google Scholar
• Tong L, Kim SH, Rosner K. Fused bi-heteroaryl substituted hydantoin compounds as TACE inhibitors. Bioorg Med Chem Lett. 2017;27:3037–3042.
   PubMed Web of Science ®Google Scholar
• Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discovery. 2008;7:255–270.
   PubMed Web of Science ®Google Scholar
• Tong L, Kim SH, Chen L. Development of a prodrug of hydantoin based TACE inhibitor. Bioorg Med Chem Lett. 2017;27:3704–3708.
   PubMed Web of Science ®Google Scholar
• Pu Y, Cao D, Xie C. Anti-arthritis effect of a novel quinazoline derivative through inhibiting production of TNF-α mediated by TNF-α converting enzyme in murine collagen-induced arthritis model. Biochem Biophys Res Commun. 2015;462:288–293.
   PubMed Web of Science ®Google Scholar
• Wu D, Gu Q1, Zhao N. Structure-based rational design of peptide hydroxamic acid inhibitors to target tumor necrosis factor-α converting enzyme as potential therapeutics for hepatitis. J Drug Target. 2015;23:936–942.
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000;28:235–242.
   PubMed Web of Science ®Google Scholar
• Wang Z, L W, Fan R. Molecular design and structural optimization of potent peptide hydroxamate inhibitors to selectively target human ADAM metallopeptidase domain 17. Comput Biol Chem. 2016;61:15–22.
   PubMed Web of Science ®Google Scholar
• Qiu Z, Yan M, Li Q, et al. Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-α converting enzyme (TACE/ADAM-17).J. J Enzyme Inhib Med Chem. 2012;27:533–540.
   PubMed Web of Science ®Google Scholar
• Udechukwu MC, Tsopmo A, Mawhinney H, et al. Inhibition of ADAM17/TACE activity by zinc-chelating rye secalin-derived tripeptides and analogues. RSC Adv. 2017;7:26361–26369.
   Web of Science ®Google Scholar
• Bandarage UK, Wang T, Come JH. Novel thiol-based TACE inhibitors. Part 2: rational design, synthesis, and SAR of thiol-containing aryl sulfones. Bioorg Med Chem Lett. 2008;18:44–48.
   PubMedGoogle Scholar
• Leung CH, Liu LJ, Lu L, et al. A metal-based tumour necrosis factor-alpha converting enzyme inhibitor. Chem Commun. 2015;51:3973–3976.
   PubMed Web of Science ®Google Scholar
• Srour N, Lebel A, McMahon S, et al. TACE/ADAM-17 maturation and activation of sheddase activity require proprotein convertase activity. FEBS Lett. 2003;554:275–283.
   PubMed Web of Science ®Google Scholar
• Wong E, Maretzky T, Peleg Y, et al. The functional maturation of A Disintegrin And Metalloproteinase (ADAM) 9, 10 and 17 requires processing at a newly identified proprotein convertase (PC) cleavage site. J Biol Chem. 2015;290:12135–12146.
   PubMed Web of Science ®Google Scholar
• Gonzales PE, Solomon A, Miller AB, et al. Inhibition of the tumor necrosis factor-alpha converting enzyme by its pro domain. J Biol Chem. 2004;279:31638–31645.
   PubMed Web of Science ®Google Scholar
• Matthews AL, Noy PJ, Reyat JS, et al. Regulation of A Disintegrin And Metalloproteinase (ADAM) family sheddases ADAM10 and ADAM17: the emerging role of tetraspanins and rhomboids. Platelets. 2017;28:333–341.
   PubMed Web of Science ®Google Scholar
• Moroy G, Martiny VY, Vayer P, et al. Toward in silico structure-based ADMET prediction in drug discovery. Drug Discov Today. 2012;17:44–55.
   PubMed Web of Science ®Google Scholar
• Sliwoski G, Kothiwale S, Meiler J. Computational methods in drug discovery. Pharmacol Rev. 2014;66:334–395.
   PubMed Web of Science ®Google Scholar
• Feng WF, Zhao YB, Huang W, et al. Molecular modeling and biological effects of peptidomimetic inhibitors of TACE activity. J Enzyme Inhib Med Chem. 2010;25:459–466.
   PubMed Web of Science ®Google Scholar
• Murumkar PR, Le L, Truong TN, et. al. Determination of structural requirements of influenza neuraminidase type A inhibitors and binding interaction analysis with the active site of A/H1N1 by 3D-QSAR CoMFA and CoMSIA modeling. Med Chem Commun. 2011;2:710–719.
   Google Scholar
• Liu S, Liu S, Wang Y. The P2/P2ʹ sites affect the substrate cleavage of TNF-α converting enzyme (TACE). Mol Immunol. 2014;62:122–128.
   PubMed Web of Science ®Google Scholar
• Baker NA, Sept D, Joseph S, et al. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci USA. 2001;98:10037–10041.
   PubMed Web of Science ®Google Scholar
• Lambert MH, Blackburn RK, Seaton TD. Substrate specificity and novel selective inhibitors of TNF-alpha converting enzyme (TACE) from two-dimensional substrate mapping. Comb Chem High Throughput Screen. 2005;8:327–339.
   PubMed Web of Science ®Google Scholar
• Kalyan Kumar G, Dhamotharan R, Kulkarni NM, et al. Embelin reduces cutaneous TNF-α level and ameliorates skin edema in acute and chronic model of skin inflammation in mice. Eur J Pharmacol. 2011;662:63–69.
   PubMed Web of Science ®Google Scholar
• Dhanjal JK, Nigam N, Sharma S, et al. Embelin inhibits TNF-α converting enzyme and cancer cell metastasis: molecular dynamics and experimental evidence. BMC Cancer. 2014;14:775.
   PubMed Web of Science ®Google Scholar
• Shoichet BK. Virtual screening of chemical libraries. Nature. 2004;432:862–865.
   PubMed Web of Science ®Google Scholar
• Caporuscio F, Tafi A. Pharmacophore modelling: a forty year old approach and its modern synergies. Curr Med Chem. 2011;18:2543–2553.
   PubMed Web of Science ®Google Scholar
• Liu LJ, Leung KH, Lin S. Pharmacophore modeling for the identification of small-molecule inhibitors of TACE. Methods. 2015;71:92–97.
   PubMed Web of Science ®Google Scholar
• Sarkate AP, Murumkar PR, Lokwani DK, et al. Design of selective TACE inhibitors using molecular docking studies: synthesis and preliminary evaluation of anti-inflammatory and TACE inhibitory activity.SAR. QSAR Environ Res. 2015;26:905–923.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Hamzeh-Mivehroud M, Sokouti B, et al. An alignment independent 3-D QSAR study on series of Hydroxamic acid based tumor necrosis factor alpha converting enzyme inhibitors. J Chemometrics. 2016;30:537–547.
   Web of Science ®Google Scholar
• Speck N, Brandsch C, Schmidt N, et al. The antiatherogenic effect of fish oil in male mice is associated with a diminished release of endothelial ADAM17 and ADAM10 substrates. J Nutr. 2015;145:1218–1226.
   PubMed Web of Science ®Google Scholar
• Sharma M, Mohapatra J, Wagh A, et al. Involvement of TACE in colon inflammation: a novel mechanism of regulation via SIRT-1 activation. Cytokine. 2014;66:30–39.
   PubMed Web of Science ®Google Scholar
• Hirata S, Murata T, Suzuki D, et al. Selective inhibition of ADAM17 efficiently mediates glycoprotein Ibα retention during ex vivo generation of human induced pluripotent stem cell-derived platelets. Stem Cells Transl Med. 2017;6:720–730.
   PubMed Web of Science ®Google Scholar
• Hedemann N, Rogmans C, Sebens S, et al. ADAM17 inhibition enhances platinum efficiency in ovarian cancer. Oncotarget. 2018;9:16043–16058.
   PubMedGoogle Scholar
• Geribaldi-Doldán N, Carrasco M, Murillo-Carretero M. Specific inhibition of ADAM17/TACE promotes neurogenesis in the injured motor cortex. Cell Death Dis. 2018;9:862.
   PubMed Web of Science ®Google Scholar
• Tape CJ, Willems SH, Dombernowsky SL. Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci USA. 2011;108:5578–5583.
   PubMed Web of Science ®Google Scholar
• Kwok HF, Botkjaer KA, Tape CJ, et al. Development of a ‘mouse and human cross-reactive’ affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy. Protein Eng Des Sel. 2014;27:179–190.
   PubMed Web of Science ®Google Scholar
• Rios-Doria J, Sabol D, Chesebrough J, et al. A monoclonal antibody to ADAM17 inhibits tumor growth by inhibiting EGFR and non-EGFR-mediated pathways. Mol Cancer Ther. 2015;14:1637–1649.
   PubMed Web of Science ®Google Scholar
• Peng L, Cook K, Xu L, et al. Molecular basis for the mechanism of action of an anti-TACE antibody. mAbs. 2016;8:1598–1605.
   PubMed Web of Science ®Google Scholar
• Dosch J, Ziemke E, Wan S, et al. Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency. Oncotarget. 2017;8:65090–65099.
   PubMedGoogle Scholar
• Saad MI, Rose-John S, Jenkins BJ. ADAM17: an emerging therapeutic target for lung cancer. Cancers (Basel). 2019;11:1218.
   Web of Science ®Google Scholar